Evidence mapPaperPMID 35203426Full record

ArticleBiomedicines2022

Proteomic Analysis of Mouse Kidney Tissue Associates Peroxisomal Dysfunction with Early Diabetic Kidney Disease.

Aggeliki Tserga, Despoina Pouloudi, Jean Sébastien Saulnier-Blache, Rafael Stroggilos, Irene Theochari, Harikleia Gakiopoulou, Harald Mischak, Jerome Zoidakis, Joost Peter Schanstra, Antonia Vlahou and 1 more

Open access · goldAbstract read
In one paragraph

Article in Biomedicines, 2022. The graph could read no effect estimate from its abstract, so it casts no vote on the map. Cited by 11 papers.

0numbers the graph read from it
0cells of the map it votes in
11citing papers in PubMed
0.9field-weighted citation impact, top 30% of its field
1 · What the graph read from it

What it found

Each row is one number read from the abstract, on the scale the paper reported it, with its interval. Left of the dashed line favours the treatment, right favours the comparator. Under each row is the sentence it came from. New to these charts? A ten-minute tutorial.

The abstract states no effect estimate the extractor could read, or names no intervention and outcome on the map, so this paper lights no cell and moves no belief. It is still indexed, cited and linked below.

2 · The registry

The trial behind it

Trials whose registry record cites this paper, or whose number appears in the abstract. A trial that started after this paper was published is citing it as background, not reporting it.

Neither the registry nor the abstract names a trial number. If this is a trial report, that itself is worth knowing.

3 · Its place in the literature

Who cites it

11 citing papers in PubMed, 11 citations in OpenAlex.

  1. Article
  2. Article
  3. Article
  4. Article
  5. Article
  6. Article
  7. Article
  8. Article
  9. Review
  10. Review
  11. Article
4 · The record

Corrections and comments

PubMed lists nothing against this paper. Absence here is not a guarantee, only a check that was made.

5 · Who and what money

Authors and funding

11 authors at 4 institutions in 3 countries.

Aggeliki TsergaDepartment of Biotechnology, Biomedical Research Foundation, Academy of Athens, Soranou Efessiou 4, 11527 Athens, Greece.ORCID 0000-0002-5531-2111
Despoina PouloudiFirst Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Jean Sébastien Saulnier-BlacheInstitut National de la Santé et de la Recherche Médicale (INSERM), U1297, Institute of Cardiovascular and Metabolic Disease, 31432 Toulouse, France.
Rafael StroggilosDepartment of Biotechnology, Biomedical Research Foundation, Academy of Athens, Soranou Efessiou 4, 11527 Athens, Greece.
Irene TheochariFirst Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Harikleia GakiopoulouFirst Department of Pathology, School of Medicine, National and Kapodistrian University of Athens, 11527 Athens, Greece.
Harald MischakMosaiques Diagnostics GmbH, 30659 Hannover, Germany.ORCID 0000-0003-0323-0306
Jerome ZoidakisDepartment of Biotechnology, Biomedical Research Foundation, Academy of Athens, Soranou Efessiou 4, 11527 Athens, Greece.ORCID 0000-0002-4557-3430
Joost Peter SchanstraInstitut National de la Santé et de la Recherche Médicale (INSERM), U1297, Institute of Cardiovascular and Metabolic Disease, 31432 Toulouse, France.
Antonia VlahouDepartment of Biotechnology, Biomedical Research Foundation, Academy of Athens, Soranou Efessiou 4, 11527 Athens, Greece.
Manousos MakridakisDepartment of Biotechnology, Biomedical Research Foundation, Academy of Athens, Soranou Efessiou 4, 11527 Athens, Greece.
Academy of Athens · GRNational and Kapodistrian University of Athens · GRUniversité Toulouse III - Paul Sabatier · FRMosaiques Diagnostics and Therapeutics (Germany) · DE

Funding

Hellenic Foundation for Research and Innovation (HFRI) and the General Secretariat for Research and Innovation (GSRI) No 695 (MolProt-CKD)
6 · The paper itself

Abstract

backgroundThe absence of efficient inhibitors for diabetic kidney disease (DKD) progression reflects the gaps in our understanding of DKD molecular pathogenesis.

methodsA comprehensive proteomic analysis was performed on the glomeruli and kidney cortex of diabetic mice with the subsequent validation of findings in human biopsies and omics datasets, aiming to better understand the underlying molecular biology of early DKD development and progression.

resultsLC-MS/MS was employed to analyze the kidney proteome of 2 DKD models: Ins2Akita (early and late DKD) and db/db mice (late DKD). The abundance of detected proteins was defined. Pathway analysis of differentially expressed proteins in the early and late DKD versus the respective controls predicted dysregulation in DKD hallmarks (peroxisomal lipid metabolism and β-oxidation), supporting the functional relevance of the findings. Comparing the observed protein changes in early and late DKD, the consistent upregulation of 21 and downregulation of 18 proteins was detected. Among these were downregulated peroxisomal and upregulated mitochondrial proteins. Tissue sections from 16 DKD patients were analyzed by IHC confirming our results.

conclusionOur study shows an extensive differential expression of peroxisomal proteins in the early stages of DKD that persists regardless of the disease severity, providing new perspectives and potential markers of diabetic kidney dysfunction.

Indexed as

biomarkerdiabetesdiabetic kidney diseaseglomerulikidneyLC–MS/MSperoxisomeproteomics

Identifiers

PMID35203426
PMCPMC8869654
OpenAlexW4220845279

What Socratic holds

Textmetadata
LicenceCC BY
Read underepoch 390

Registered trials

None linked

Read under generation 80e0d062 · epoch 390. Bibliography from PubMed, PubMed Central and OpenAlex; grants from NIH RePORTER; trial links from ClinicalTrials.gov; estimates, votes and beliefs from the Socratic graph.